Sait Yeşillik

Sait Yeşillik

Auto-generated profile, based on publicly available information

Sait Yeşillik

Department of Immunology and Allergy, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Annals of Medicine
Verified
Journal Article
Open access
ASAli Selcuk
Ali Selcuk
ABAbdullah Baysan
Abdullah Baysan
SYSait Yesillik
Sait Yesillik
FDFevzi Demirel
Fevzi Demirel
OKOzgur Kartal
Ozgur Kartal
OSOsman Sener
Osman Sener
Venom immunotherapy (VIT) is an effective treatment in the patients at high risk of anaphylaxis or life-threatening systemic reactions due to Hymenoptera venom allergy. But, systemic and large loca...

5 November 2024 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
FKFikriye handan Kalkan
Fikriye handan Kalkan
SYSait Yeşillik
Sait Yeşillik
FDFevzi Demirel
Fevzi Demirel
ESEzgi Sönmez
Ezgi Sönmez
YBYasemin AKGUL BALABAN
Yasemin AKGUL BALABAN
ÖKÖzgür Kartal
Özgür Kartal
Chronic spontaneous urticaria (CSU) is a clinical condition that affects patients quality of life. Omalizumab is preferred in antihistamines resistant CSU cases. Urticaria activity score-7 (UAS-7) is a scale that shows the severity of the disease. The authors aimed to compare the long-term (60 months) efficacy and side effects of 150 mg and 300 mg doses of omalizumab in patients with CSU. 108 patients followed up at the clinic with the diagnosis of CSU were included. Omalizumab was started in patients who were resistant to conventional CSU treatment. Two groups were formed to receive 150 mg and 300 mg doses of omalizumab. Urticaria activity score (UAS-7), antihistamine usage, time to achieve disease-free stage, relapse after treatment, and side effects of omalizumab treatment were compared in the two groups. There were no statistically significant differences between the groups regarding basal characteristics and laboratory findings. Average follow-up time was sixty months. UAS-7 scores were similar in the follow-up. There were no adverse events in both groups. Retroactive design and single-center nature to reach a more significant number of patients. Lack of patients receiving the lowest dose 75 mg and the highest dose 600 mg of omalizumab. Absence of total body mass indexes of all patients. Besides, the use of distinct drugs may contribute to non confident results and is another limitation of this study. Since there is no significant difference between 150-300 mg omalizumab doses regarding long-term treatment efficacy and side effects in CSU patients, starting treatment with a 150 mg dose may be suitable. In patients who do not respond to 150 mg, the omalizumab dose can be increased to 300 mg. It will prevent unpredictable dose and time-dependent complications and will be a cost-effective approach even in strong economies.

9 September 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
NENazlı Ercan
Nazlı Ercan
SYSait Yeşillik
Sait Yeşillik
FDFevzi Demirel
Fevzi Demirel
NTNihan Tırık
Nihan Tırık
ÖKÖzgür Kartal
Özgür Kartal

17 August 2020 in Asthma Allergy Immunology
Verified
Journal Article
Closed access
PDF file
ÖKÖzgür Kartal
Özgür Kartal
GAGökhan Aytekin
Gökhan Aytekin
ÜAÜmit Aydoğan
Ümit Aydoğan
OSOktay Sari
Oktay Sari
SYSait Yeşillik
Sait Yeşillik
FDFevzi Demirel
Fevzi Demirel
Symptoms and Awareness of Latex Allergy Among Healthcare Workers

1 September 2020 in Gulhane Medical Journal
Verified
Journal Article
Closed access
SYSait Yeşillik
Sait Yeşillik
MAMelih Alömeroğlu
Melih Alömeroğlu
BYBirol YILDIZ
Birol YILDIZ
BBBilgin Bahadır Başgöz
Bilgin Bahadır Başgöz
MGMustafa Gülşen
Mustafa Gülşen

1 July 2026 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
FKFikriye handan Kalkan
Fikriye handan Kalkan
SYSait Yeşillik
Sait Yeşillik
FDFevzi Demirel
Fevzi Demirel
ESEzgi Sönmez
Ezgi Sönmez
ASAli Selçuk
Ali Selçuk
ÖKÖzgür Kartal
Özgür Kartal
Introduction: Primary immunodeficiency (PID) is a heterogeneous group of genetic disorders characterized by recurrent infections and immune dysregulation. Despite advances in therapy, many patients experience impaired quality of life (QoL), fatigue, and sleep disturbances. This study aimed to evaluate sleep quality, fatigue, and health-related QoL in adults with PID and to explore the associations between comorbidities and treatment modalities.Materials and Methods: This retrospective, observational, single-center study was conducted at the University of Health Sciences, Gülhane Training and Research Hospital between May and August 2024. Forty-nine adult patients with PID, diagnosed according to international criteria, completed validated questionnaires: the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and SF-36 QoL scale. Clinical and demographic data were retrieved from the medical records. Statistical analyses included t-tests, Mann–Whitney U, chi-square, and Pearson’s correlation, with significance set at P < 0.05.Results: Of 49 patients (55.1% males, mean follow-up 9.9 years), 36.7% had poor sleep quality, 42.9% reported severe fatigue, 49% showed impaired SF-36 physical scores, and 87.8% had preserved mental scores. Poor sleep quality was correlated positively with fatigue (r = 0.623, P < 0.001) and negatively correlated with physical QoL (r = −0.491, P < 0.001). Patients with autoimmune and inflammatory bowel disease had significantly worse PSQI and FSS scores, whereas bronchiectasis was associated with reduced SF-36 physical scores. No differences were observed between the IVIG and SCIG groups in fatigue or mental scores; however, SCIG recipients had significantly higher physical scores (P = 0.018).Conclusion: Patients with PID experience substantial impairment in physical QoL, with fatigue and poor sleep quality frequently coexisting. Comorbidities, such as autoimmunity, bronchiectasis, and inflammatory bowel disease, exacerbate these impairments. SCIG therapy confers better physical outcomes than IVIG therapy. Comprehensive care strategies that address psychosocial and physical health are essential for the management of PID.